{"drugs":["Corifollitropin Alfa"],"mono":{"0":{"id":"930364-s-0","title":"Generic Names","mono":"Corifollitropin Alfa"},"1":{"id":"930364-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930364-s-1-4","title":"Adult Dosing","mono":"<ul><li>Corifollitropin alfa has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU).<\/li><li><b>Ovulation induction, Assisted reproductive technology in combination with gonadotropin-releasing hormone antagonist:<\/b> (36 years or younger and 60 kg or less) Stimulation day 1, 100 mcg subQ single injection during early follicular phase of menstrual cycle; stimulation day 5 or 6, start gonadotropin-releasing hormone antagonist; stimulation day 8, give recombinant follicle stimulating hormone 150 international units subQ daily (dose for normal responders) until final oocyte maturation triggered (3 follicles of 17 mm or greater), then hCG 5000 to 10,000 international units subQ same day or day after final maturation (European Medicines Agency-approved dosing)<\/li><li><b>Ovulation induction, Assisted reproductive technology in combination with gonadotropin-releasing hormone antagonist:<\/b> (Older than 36 years and 50 kg or more, OR any age and greater than 60 kg) Stimulation day 1, 150 mcg subQ single injection during early follicular phase of menstrual cycle; stimulation day 5 or 6, start gonadotropin-releasing hormone antagonist; stimulation day 8, give recombinant follicle stimulating hormone 150 international units subQ daily (dose for normal responders) until final oocyte maturation triggered (3 follicles of 17 mm or greater), then hCG 5000 to 10,000 international units subQ same day or day after final maturation (European Medicines Agency-approved dosing)<\/li><\/ul>"},"2":{"id":"930364-s-1-6","title":"Dose Adjustments","mono":"<b>Renal impairment:<\/b> Use not recommended "},"3":{"id":"930364-s-1-7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Ovulation induction, Assisted reproductive technology in combination with gonadotropin-releasing hormone antagonist<br\/>"}}},"3":{"id":"930364-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930364-s-3-9","title":"Contraindications","mono":"<ul><li>abnormal vaginal bleeding (not menstrual) without known or diagnosed cause<\/li><li>controlled ovarian stimulation, previous cycle resulting in 30 or more follicles measuring 11 mm or greater via ultrasound<\/li><li>fibroid tumors of the uterus incompatible with pregnancy<\/li><li>follicle count, basal antral, greater than 20<\/li><li>history of ovarian hyperstimulation syndrome<\/li><li>hypersensitivity to corifollitropin alfa or any component of the product<\/li><li>ovarian cysts or enlarged ovaries<\/li><li>ovarian failure, primary<\/li><li>reproductive organ malformations incompatible with pregnancy<\/li><li>tumors of the ovary, breast, uterus, pituitary, or hypothalamus<\/li><\/ul>"},{"id":"930364-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- thromboembolic events, in association with ovarian hypersensitivity syndrome and independently, have been reported; increased risk with personal or family history of thrombolic events, severe obesity, or thrombophilia<\/li><li>Renal:<\/li><li>-- renal impairment, use not recommended<\/li><li>Reproductive:<\/li><li>-- ovarian hyperstimulation syndrome, in rare cases associated with venous or arterial thromboembolism, may occur; monitoring recommended and dose adjustment or therapy withholding may be necessary<\/li><li> --congenital malformations; possible increased risk after assisted reproductive technology<\/li><li>-- first cycle of ovarian stimulation in women with unknown risk factors for high ovarian response; increased risk for ovarian hyperstimulation syndrome; monitoring recommended<\/li><li>-- infertile women undergoing assisted reproductive technology may increase risk of ectopic pregnancies; monitoring recommended<\/li><li>-- multiple pregnancies and births have been reported<\/li><li>--ovarian and other reproduction system neoplasms, benign and malignant, have been reported after multiple treatments<\/li><li>Concomitant use:<\/li><li>-- concomitant use with gonadotropin releasing hormone agonists not recommended<\/li><\/ul>"},{"id":"930364-s-3-11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"930364-s-3-12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"5":{"id":"930364-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Nausea (2.3%)<\/li><li><b>Musculoskeletal:<\/b>Discomfort, In pelvis (6%), Pain in pelvis (2.9%)<\/li><li><b>Neurologic:<\/b>Headache (4%)<\/li><li><b>Reproductive:<\/b>Breast tenderness (1.3%)<\/li><li><b>Other:<\/b>Fatigue (1.5%)<\/li><\/ul><b>Serious<\/b><br\/><b>Reproductive:<\/b>Ovarian hyperstimulation syndrome (4.3%), Torsion of ovary (0.1% to less than 1%)<br\/>"},"6":{"id":"930364-s-6","title":"Drug Name Info","sub":{"2":{"id":"930364-s-6-19","title":"Class","mono":"<ul><li>Female Reproductive Agent<\/li><li>Human Follicle Stimulating Hormone<\/li><\/ul>"},"3":{"id":"930364-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"930364-s-9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>Single-use, 0.5-mL prefilled syringe for subQ administration only, preferably in abdominal wall<\/li><li>Self- or partner-administration is acceptable if adequately trained.<\/li><\/ul>"}}}